Aviado · Research
Longevity Daily
Wednesday, October 7, 2026
Listen
Today's Brief
GLP-1 drugs don't just shrink waistlines — Novo Nordisk and Eli Lilly now show they reduce molecular markers of biological age, making today's lead one to save. The 2026 Nobel Prize in Physiology goes to optogenetics pioneers, with real implications for treating Alzheimer's and Parkinson's. A small group of longevity insiders has reportedly become the first humans to receive partial epigenetic reprogramming with AAV vectors — the field's most ambitious intervention arriving in people. Aviado's deep dive on butyrate explains why the same dose can lower blood pressure for one person and raise it for another.
10 stories3 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Optogenetics Wins the 2026 Nobel Prize in Physiology — and Brain Disease Treatment Will Never Be the Same
The 2026 Nobel Prize in Physiology or Medicine goes to the scientists behind optogenetics, a technique that uses light pulses to switch individual neurons on or off with millisecond precision. Beyond its role as a research tool, optogenetics is now being tested as a treatment for epilepsy, depression, and neurodegenerative disorders — with early clinical work suggesting it can restore brain function where drugs have failed. For anyone tracking the future of Alzheimer's and Parkinson's treatment, this is the foundational technology shaping what comes next.
Read more →The Same Inflammation That Weakens Your Bones May Also Be Degrading Your Brain
A new review makes the case that inflammaging — chronic, low-grade systemic inflammation driven by senescent cells — simultaneously drives both osteoporosis and neurodegenerative cognitive decline. The link is bidirectional: bone loss accelerates brain aging, and brain inflammation worsens skeletal health, with the senescence-associated secretory phenotype (SASP) acting as the shared culprit. For anyone managing bone density or cognitive risk, this framework suggests that targeting senescent cell burden could address both conditions at once.
Read more →NMN for Menopausal Brain Fog: Promising Rationale, Still-Thin Evidence
NAD+ declines with age and drops further during menopause, giving NMN supplements a plausible biological rationale for women experiencing brain fog, poor sleep, and low energy. The problem is that clinical trial data specific to menopausal women remains sparse, meaning dosing, timing, and expected benefits are still largely extrapolated from broader NAD+ research. If you're considering NMN, experts suggest starting low, tracking symptoms carefully, and treating it as an experiment — not a prescription.
Read more →Supplements & Compounds
Your Gut's Butyrate Signal — Not the Supplement — Is What Determines If It Works
Taking a butyrate supplement doesn't guarantee results: research shows that fecal butyrate levels almost perfectly predict whether you'll respond, and the same dose that lowers blood pressure in one person can raise it by 5 mmHg in another. Aviado's analysis traces this to individual variation in gut absorption and butyrate utilization, and offers a concrete protocol: start with 500–1,000 mg of enteric-coated sodium butyrate, measure fecal butyrate before and after four to eight weeks, and only continue if your signal rises. If it doesn't, the better move is targeting the microbiome interventions that help your gut produce butyrate naturally.
Read the full Aviado analysis →Creatine Builds Muscle Even Without Exercise, 12-Week Trial Finds
A new 12-week controlled trial found that middle-aged adults who took creatine without any structured exercise program still gained measurable muscle mass and strength — though gains were greater when workouts were added. This is particularly relevant for people who are sedentary due to illness, injury, or limited mobility, where preserving muscle matters most. For active people over 45, the findings add to an already strong evidence base for creatine as a cornerstone supplement.
Read more →Research & Papers
GLP-1 Weight-Loss Drugs Show Early Signs of Slowing Biological Aging
Novo Nordisk and Eli Lilly have released data showing that their GLP-1 receptor agonist drugs — semaglutide and tirzepatide — reduce molecular markers of biological age as measured by aging clocks, not just body weight and metabolic markers. The findings, reported by MIT Technology Review, suggest these blockbuster drugs may be doing something more fundamental: resetting the pace of aging itself. These are company-sponsored findings not yet published in peer-reviewed form, so independent replication will be critical. Still, for the millions already taking GLP-1 drugs for weight or diabetes management, this adds a compelling new dimension to the conversation.
Read more →First Humans Have Reportedly Undergone Partial Epigenetic Reprogramming With AAV Vectors
According to the KHL Foundation, a small number of individuals in the longevity community have become the first to receive partial epigenetic reprogramming treatments using adeno-associated viral (AAV) vectors — predating the formal Life Biosciences clinical trial for optic neuropathy. The treatments were administered through experienced medical tourism networks rather than regulated trials, so peer-reviewed data is not yet available, though participants may publish results over time. This is arguably the most significant self-experimentation story in longevity science since early gene therapy, and it signals that the field's most ambitious interventions are reaching humans faster than regulatory timelines allow.
Read more →Better Survival in Mice Doesn't Mean the Senolytic Vaccine Actually Worked
A new letter in the Journal of Translational Medicine argues that a widely-cited senolytic vaccine study produced real survival benefits in mice but failed to demonstrate its stated mechanism — selective clearance of senescent cells. The distinction matters enormously: if survival improved for reasons other than senolysis, the result does not validate the approach for human trials. It's a pointed reminder that mechanism and outcome are not the same thing, and that the field needs more rigorous biomarker standards before translating mouse senolytic results to the clinic.
Read more →Lifestyle & Nutrition
Zone 2 Cardio Explained: The Science Behind the Training Method Peter Attia Won't Stop Talking About
Zone 2 — the cardio intensity where you're working hard enough to burn fat but can still hold a full conversation — has become the longevity training protocol of the moment, championed by Peter Attia and grounded in physiology research by Iñigo San Millán of the University of Colorado. The mechanism: sustained low-intensity effort trains your mitochondria to oxidize fat more efficiently, building the metabolic base that underpins VO2 max, insulin sensitivity, and long-term cardiovascular health. If you're not currently doing it, aim for 45–60 minutes, three to four times per week, at a pace that feels almost too easy.
Read more →Industry & Policy
Bausch + Lomb Upgrades the Eye Health Gold Standard With a New AREDS3 Formula
Bausch + Lomb has launched PreserVision AREDS3, adding a B-vitamin complex to the long-established AREDS2 formula after data from the Women's Antioxidant and Cardiovascular Study showed a statistically significant association between B-vitamin supplementation and reduced age-related macular degeneration (AMD) risk. AREDS2 has been the clinical benchmark for AMD prevention for years, and this update signals the category is still actively evolving. Longer-term data will be needed to confirm whether the B-vitamin addition meaningfully improves outcomes — but if you or a family member already takes PreserVision, it's worth discussing the new formulation with your eye care provider.
Read more →